Medicine and Dentistry
Odds Ratio
50%
Cross Sectional Study
50%
Observational Study
50%
Multiple Myeloma
50%
Portal Vein Thrombosis
50%
Extramammary Paget's Disease
50%
COVID-19 Vaccination
50%
Oral Cancer
50%
Synovial Sarcoma
50%
Thoracic Wall
50%
Transverse Colon
50%
Spirochete Infection
50%
Retrospective Cohort Study
50%
Rectum Cancer
50%
Gene Expression Profiling
50%
Angiosarcoma
50%
Neoplasm
36%
Rectal Bleeding
33%
Metastatic Carcinoma
33%
Diseases
32%
Lenalidomide
25%
Patient with Type 2 Diabetes
25%
Intestinal Wall
25%
Brachyspira
25%
Blood Transfusion
20%
Surgical Infection
20%
Urinary Tract Infection
20%
Acute Kidney Injury
20%
Bortezomib
18%
Progression Free Survival
18%
Overall Survival
18%
Telemedicine
16%
Colonoscopy
16%
Surgery
16%
Colectomy
16%
Outpatient
16%
Abdominal Pain
16%
Histopathology
16%
M Protein
12%
Adverse Event
12%
Open Surgery
12%
Coloproctology
12%
Prevalence
12%
Cardiovascular System
12%
Rectum Anterior Resection
12%
Postoperative Complication
10%
Chi Square Test
10%
Surgical Mortality
10%
Immunomodulatory Drug
10%
Art Therapy
10%
Case Fatality Rate
10%
Immunohistochemistry
10%
Serositis
10%
Family History
10%
Immune Response
10%
Ciclonicate
10%
RNA Sequence
10%
Lymphedema
10%
Breast Cancer
10%
Differential Diagnosis
10%
Malignant Neoplasm
10%
Leukemia
10%
Transcriptome
10%
Bone Lesion
6%
Biochemical Recurrence
6%
Neutropenia
6%
Carfilzomib
6%
Immunoglobulin A
6%
Treatment Withdrawal
6%
Time to Treatment
6%
Proteasome Inhibitor
6%
Daratumumab
6%
Population Research
6%
Retrospective Study
6%
Cancer Therapy
6%
Cancer Research
6%
Kaplan Meier Method
6%
Biological Marker
6%
Symptomatic Treatment
6%
Immunoglobulin
6%
Anemia
6%
Survival Time
6%
Youden Index
5%
Diagnostic Test
5%
Immunology and Microbiology
Experimental Model
100%
Receptor Gene
100%
Cell Line
50%
Multiple Myeloma
50%
Bovine Leukemia Virus
50%
Breast Tissue
42%
Brachyspira
25%
Spirochaete
25%
Transcriptomics
25%
mRNA Expression Level
25%
Quantitative Reverse Transcription Polymerase Chain Reaction
25%
Lenalidomide
25%
Overall Survival
18%
Progression Free Survival
18%
Gene Expression
12%
Bovine
10%
Cell Transformation
10%
DNA Damage
10%
Virus Detection
10%
Immunoglobulin A
6%
Immunoglobulin Blood Level
6%
Daratumumab
6%
Survival Time
6%
Population Research
6%
Proteasome
6%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
50%
Observational Study
50%
Vaccination Policy
50%
Bovine Leukemia Virus
50%
Lenalidomide
25%
Progression Free Survival
18%
Bortezomib
18%
Overall Survival
18%
M Protein
12%
Adverse Event
12%
Malignant Neoplasm
12%
Cell DNA
10%
Virus Infection
10%
Glycosylated Hemoglobin
8%
Case Fatality Rate
8%
Immunoglobulin
6%
Immunoglobulin A
6%
Bone Lesion
6%
Anemia
6%
Carfilzomib
6%
Daratumumab
6%
Neutropenia
6%
Proteasome Inhibitor
6%
Survival Time
6%
Biochemical Recurrence
6%
Biological Marker
6%
Retrospective Study
6%
Population Study
6%